Fortress Biotech

The cytomegalovirus (CMV) infections market is projected to grow at a CAGR of 4.32% from 2024 to 2034, driven by increased exposure to infected fluids, weakened immune systems, and the adoption of antiviral drugs and therapies. CMV, a herpesvirus, spreads through bodily fluids and can cause severe symptoms. The U.S. leads in patient pool and market size. Recent developments include new treatments and vaccines, highlighting the market's dynamic nature and potential for growth.

Checkpoint Therapeutics outperforms Tyra Biosciences in 6 out of 11 factors, including higher revenue, earnings, and potential stock upside. Despite Tyra's lower P/E ratio and higher institutional ownership, Checkpoint's greater volatility and analyst favorability suggest it's the more promising investment.

UNLOXCYT™ (cosibelimab-ipdl) is the first FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma (cSCC), offering a new immunotherapy option with a dual mechanism of action and a compelling safety profile. It's administered intravenously every three weeks.

Checkpoint Therapeutics announced FDA approval of UNLOXCYT™ (cosibelimab-ipdl) for treating adults with metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) not eligible for surgery or radiation. UNLOXCYT is the first PD-L1 blocking antibody for this indication, offering a new immunotherapy option with a unique mechanism of action. The approval marks Checkpoint's entry into a $1 billion market, with plans for commercial launch underway.

Checkpoint Therapeutics announced FDA approval for UNLOXCYT™ (cosibelimab-ipdl) to treat adults with metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) not eligible for curative surgery or radiation. UNLOXCYT, a PD-L1 blocking antibody, offers a new treatment option with a recommended dosage of 1,200 mg every three weeks.

Fortress Biotech's Q3 2024 revenue was $14.6m, down 7.1% YoY, with a net loss of $12.9m, up 82% YoY. EPS missed estimates by 28%, and revenue by 55%. Shares are down 16% in a week. Future revenue growth is forecast at 42% p.a., compared to 21% for the US Biotechs industry.

Fortress Biotech announces FDA approval for Emrosi to treat rosacea and potential approval for cosibelimab for cutaneous squamous cell carcinoma, with financial results and recent corporate highlights for Q3 2024.

Journey Medical Corporation announced FDA approval of Emrosi™ for rosacea treatment, expecting launch in Q1-Q2 2025, and reported $14.6 million in Q3 2024 revenues.

U.S. FDA approved Emrosi™ for rosacea treatment, with a launch expected in 2025. Journey Medical reported $14.6M in Q3 2024 revenues, a 4% decrease from 2023. The company focuses on dermatology products, with Emrosi seen as a potential best-in-class oral medication for rosacea.